Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 1Neoplasms, Germ Cell and Embryonal 1Nausea 1Glioma 1

Interventions

Cisplatin 13Etoposide 11Paclitaxel 8Cyclophosphamide 7Carboplatin 7Ifosfamide 6etoposide phosphate 5Granulocyte Colony-Stimulating Factor 5Gemcitabine 5pembrolizumab 4fludarabine 4Sirolimus 4Bleomycin 4fludarabine phosphate 3Sunitinib 3Oxaliplatin 3Mesna 3Melphalan 3Filgrastim 3Drug Therapy 3Brentuximab Vedotin 3Bevacizumab 3Automobiles 3130-nm albumin-bound paclitaxel 3tremelimumab 2sodium thiosulfate 2ribociclib 2pralsetinib 2pegfilgrastim 2lutetium Lu 177 dotatate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Germ Cell and Embryonal × rolapitant × Clear all
NCT03960151 2019-05-22

Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy

Hoosier Cancer Research Network

Phase 2 Withdrawn

Neoplasms, Germ Cell and Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡